NYSEARCA:LCTX

Lineage Cell Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy LCTX

*Your capital is at risk

$1.74

-0.140 (-7.45%)

At Close: Nov 17, 2025

Lineage Cell Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.95. In total, the insiders bought 46.57M and sold 60.57K LCTX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.95
● Buy	46.57M shares
● Sell	60.57K shares
92% Buy Activity Negligible or No Correlation
Sell Signal Low Confidence Feb 11, 2025 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 99.95. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 01, 2025 Buy	OPTION TO PURCHASE COMMON SHARES A-Award	Bradsher Neal C	Director	75 000 Value: $67.3K
Jul 01, 2025 Buy	OPTION TO PURCHASE COMMON SHARES A-Award	Bradsher Neal C	Director	75 000 Value: $67.3K
Jul 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Amin Dipti Director	Director	75 000 Value: $67.3K
Jul 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Jayasuriya Anula Director	Director	75 000 Value: $67.3K
Jul 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Russell Angus C. Director	Director	75 000 Value: $67.3K
Jul 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Mulroy Michael H. Director	Director	75 000 Value: $67.3K
Jul 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Andrews Deborah J Director	Director	75 000 Value: $67.3K
Jul 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Andrews Deborah J Director	Director	75 000 Value: $67.3K
Jul 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Mulroy Michael H. Director	Director	75 000 Value: $67.3K
Jul 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Russell Angus C. Director	Director	75 000 Value: $67.3K
Jul 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Jayasuriya Anula Director	Director	75 000 Value: $67.3K
Jul 01, 2025 Buy	Stock Option (Right to Buy) A-Award	Amin Dipti Director	Director	75 000 Value: $67.3K
Mar 10, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Culley Brian M President And CEO	CEO / President	2 300 000 Value: $1.22M
Mar 10, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Howe Jill Ann Chief Financial Officer	C-Suite Officer	750 000 Value: $397.5K
Mar 10, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Samuel George A. Iii General Counsel And Secretary	Officer	750 000 Value: $397.5K
Mar 10, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Samuel George A. Iii General Counsel And Secretary	Officer	750 000 Value: $397.5K
Mar 10, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Howe Jill Ann Chief Financial Officer	C-Suite Officer	750 000 Value: $397.5K
Mar 10, 2025 Buy	Employee Stock Option (Right to Buy) A-Award	Culley Brian M President And CEO	CEO / President	2 300 000 Value: $1.22M
Feb 11, 2025 Buy	Common Shares M-Exempt	Samuel George A. Iii General Counsel	Officer	6 076 Value: $4K
Feb 11, 2025 Sell	Common Shares F-InKind	Samuel George A. Iii General Counsel	Officer	2 440 Value: $2K
Feb 11, 2025 Buy	Restricted Stock Units M-Exempt	Samuel George A. Iii General Counsel	Officer	6 076 Value: $4K
Feb 11, 2025 Buy	Common Shares M-Exempt	Culley Brian M President And CEO	CEO / President	31 249 Value: $20.4K
Feb 11, 2025 Sell	Common Shares F-InKind	Culley Brian M President And CEO	CEO / President	12 547 Value: $8K
Feb 11, 2025 Buy	Restricted Stock Units M-Exempt	Culley Brian M President And CEO	CEO / President	31 249 Value: $20.4K
Feb 11, 2025 Buy	Restricted Stock Units M-Exempt	Culley Brian M President And CEO	CEO / President	31 249 Value: $20.4K

About Insider Power

Insider Power is a proprietary algorithm developed by Stockinvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT LINEAGE CELL THERAPEUTICS, INC.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa mul...

Read Full Profile Here